**RESULTS**

Table 1: Summary of ceftobiprole activity tested against pathogens from patients hospitalized with bacterial pneumonia in Europe and Israel (2013).

Table 2: Activity of ceftobiprole and comparator antimicrobial agents when tested against Gram-positive pathogens from patients hospitalized with pneumonia in Europe and Israel (2013).

**CONCLUSIONS**

Ceftobiprole exhibited potent in vitro activity against a broad range of Gram-positive and negative pathogens isolated from European and Israeli patients hospitalized with pneumonia during 2013. All S. aureus strains were susceptible to ceftobiprole. Ceftobiprole also exhibited potent in vitro activity against Gram-negative bacteria including H. influenzae, non-ESBL-γ-lactamase E. coli and K. pneumoniae. Additionally, P. aeruginosa, cephalosporin-resistant β-lactamase-positive (9) 0 (0.0) 0 (0.0) 6 (66.7) 2 (88.9) 1 (100.0) -- -- -- -- -- 0.03 -- 1

- **Ceftobiprole** (MIC<sub>50</sub>/MIC<sub>90</sub>, 0.5/2 mg/L; 100.0% susceptible; 0.03/0.5 mg/L; 100.0% susceptible)
- **Ceftazidime** (MIC<sub>50</sub>/MIC<sub>90</sub>, 0.12/1 mg/L; 100.0% susceptible; 0.03/0.5 mg/L; 100.0% susceptible)
- **Tetracycline** (MIC<sub>50</sub>/MIC<sub>90</sub>, 32/32 mg/L; 0.0% susceptible; 0.25/32 mg/L; 27.3% susceptible)
- **Levofloxacin** (MIC<sub>50</sub>/MIC<sub>90</sub>, >4/>4 mg/L; 100.0% susceptible; 100.0% susceptible).

**ACKNOWLEDGMENT**

This study was supported by Balesa Pharmaceuticals International Ltd.